Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

584 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The effect of exercise and educational programs for breast cancer patients on the development of breast cancer-related lymphoedema: secondary endpoint from a randomized controlled trial in the Setouchi Breast Project-10.
Nakamoto S, Iwamoto T, Taira N, Kajiwara Y, Kawada K, Takabatake D, Miyoshi Y, Kubo S, Suzuki Y, Yamamoto M, Ogasawara Y, Hatono M, Yoshitomi S, Hara K, Sasahara A, Ohsumi S, Ikeda M, Doihara H, Mizota Y, Yamamoto S, Shien T, Toyooka S. Nakamoto S, et al. Among authors: ogasawara y. Breast Cancer. 2024 Sep;31(5):969-978. doi: 10.1007/s12282-024-01610-5. Epub 2024 Jul 9. Breast Cancer. 2024. PMID: 38980571 Clinical Trial.
Baseline gut microbiota as a predictive marker for the efficacy of neoadjuvant chemotherapy in patients with early breast cancer: a multicenter prospective cohort study in the Setouchi Breast Project-14.
Nakamoto S, Kajiwara Y, Taniguchi K, Hida AI, Miyoshi Y, Kin T, Yamamoto M, Takabatake D, Kubo S, Hikino H, Ogasawara Y, Ikeda M, Doihara H, Shien T, Taira N, Iwamoto T, Toyooka S. Nakamoto S, et al. Among authors: ogasawara y. Breast Cancer Res Treat. 2024 Nov;208(1):67-77. doi: 10.1007/s10549-024-07395-7. Epub 2024 Jun 18. Breast Cancer Res Treat. 2024. PMID: 38888797
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
Takashima T, Mukai H, Hara F, Matsubara N, Saito T, Takano T, Park Y, Toyama T, Hozumi Y, Tsurutani J, Imoto S, Watanabe T, Sagara Y, Nishimura R, Shimozuma K, Ohashi Y; SELECT BC Study Group. Takashima T, et al. Lancet Oncol. 2016 Jan;17(1):90-8. doi: 10.1016/S1470-2045(15)00411-8. Epub 2015 Nov 27. Lancet Oncol. 2016. PMID: 26617202 Clinical Trial.
Biosynthesis of lactacystin as a proteasome inhibitor.
Tsunoda T, Furumura S, Yamazaki H, Maruyama C, Hamano Y, Ogasawara Y, Dairi T. Tsunoda T, et al. Among authors: ogasawara y. Commun Chem. 2025 Jan 13;8(1):9. doi: 10.1038/s42004-025-01406-4. Commun Chem. 2025. PMID: 39806036 Free PMC article.
584 results